Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

Medicine and Dentistry

• Inflammatory Bowel Disease 100%
• Stem Cell 33%
• Glucocorticoid 33%
• Innate Immunity 33%
• Vitamin D 33%
• Crohn's Disease 33%
• Adaptive Immunity 33%
• Tumor Necrosis Factor 33%
• Immunology 33%
• Inflammatory Cytokine 33%
• Ulcerative Colitis 33%
• Probiotic Agent 33%
• Interleukin 12 33%
• Prebiotic Agent 33%
• Mucosal Immune Response 33%
• 4-Aminosalicylic Acid 33%
• Fecal Microbiota Transplantation 33%
• Dietary Supplement 33%
• Interleukin 23 33%
• Janus Kinase Inhibitor 33%
• Signal Transduction 33%
• Methotrexate 33%
• Integrin 33%
• Monoclonal Antibody 33%
• Mercaptopurine 33%

Immunology and Microbiology

• Inflammatory Bowel Disease 100%
• Monospecific Antibody 66%
• Intestine Flora 66%
• Innate Immune System 33%
• Adaptive Immune System 33%
• Interleukin 12 33%
• Tumor Necrosis Factor 33%
• Mucosal Immune Response 33%
• Immunology 33%
• Monoclonal Antibody 33%
• Probiotic 33%
• Microorganism 33%
• Stem Cell 33%
• Methotrexate 33%
• Feces microflora 33%
• Proinflammatory Cytokine 33%
• Signal Transduction 33%
• Integrin 33%
• Crohn's Disease 33%
• Ulcerative Colitis 33%
• Interleukin 23 33%
• Colon Flora 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Intestine Flora 66%
• Microorganism 33%
• Integrin 33%
• Dietary Supplement 33%
• Aminosalicylic Acid 33%
• Feces microflora 33%
• Colon Flora 33%
• Vitamin D 33%
• Probiotic Agent 33%
• Prebiotic Agent 33%
• Ulcerative Colitis 33%
• Glucocorticoid 33%
• Methotrexate 33%
• Cytokine 33%
• Tumor Necrosis Factor 33%
• Monoclonal Antibody 33%
• Janus Kinase Inhibitor 33%
• Crohn's Disease 33%
• Interleukin 12 33%
• Mercaptopurine 33%
• Interleukin 23 33%